JAK inhibition therapy for intractable cutaneous infectious granulomatosis with unknown etiology: a case report

Suiting Ao; Mingjia Hu; Fanli Xu; Shuang Lyv; F. Zhang; H Liu

doi:10.1080/09546634.2026.2637510

March 13, 2026Journal of Dermatological TreatmentOpen Access

JAK inhibition therapy for intractable cutaneous infectious granulomatosis with unknown etiology: a case report

View Full Paper

Ask AI

Bookmark

Share

Key Points

To explore the effectiveness of JAK inhibition therapy for treating intractable cutaneous granulomatosis with unknown etiology.
Case report detailing treatment with JAK inhibition using upadacitinib.
Patient presented with refractory granulomatosis and excessive immune response.
Treatment effects monitored over time.
Upadacitinib treatment resulted in notable improvement in symptoms.
Patient showed reduced immune response despite absence of identifiable pathogens.

Implication

Case report shows JAK inhibition with upadacitinib improves symptoms in patients with granulomatosis, suggesting a new treatment avenue.

Abstract

This case-report highlights a potential role for JAK inhibition, upadacitinib, in managing refractory cutaneous granulomatosis with an excessive immune response despite no identifiable pathogen and pathogen clearance.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ao et al. (2026) studied this question.

synapsesocial.com/papers/69b5ff4f83145bc643d1ba41 https://doi.org/10.1080/09546634.2026.2637510

View Full Paper

Ask AI

Bookmark

Share

JAK inhibition therapy for intractable cutaneous infectious granulomatosis with unknown etiology: a case report

Key Points

Implication

Abstract

Discussion

Cite This Study

JAK inhibition therapy for intractable cutaneous infectious granulomatosis with unknown etiology: a case report

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading